{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:41:41Z","timestamp":1758595301897,"version":"3.44.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.steroids.2020.108657","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T11:41:39Z","timestamp":1589802099000},"page":"108657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Facial synthesis of key intermediate of obeticholic acid via Pd-catalyzed Kumada-Tamao-Corriu cross-coupling reaction"],"prefix":"10.1016","volume":"160","author":[{"given":"Xiangjie","family":"Di","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.steroids.2020.108657_b0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/138955711796355258","article-title":"Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA","volume":"11","author":"Fiorucci","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"issue":"17\u201318","key":"10.1016\/j.steroids.2020.108657_b0010","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Disc. Today"},{"issue":"9972","key":"10.1016\/j.steroids.2020.108657_b0015","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.steroids.2020.108657_b0020","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure\u2212 activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.steroids.2020.108657_b0025","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.steroids.2020.108657_b0030","doi-asserted-by":"crossref","first-page":"G940","DOI":"10.1152\/ajpgi.00398.2012","article-title":"Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids","volume":"304","author":"Zhang","year":"2013","journal-title":"Am. J. Physiol. Gastrointestinal Liver Physiol."},{"key":"10.1016\/j.steroids.2020.108657_b0035","unstructured":"R. Pellicciari, Steroids as agonists for FXR, Google Patents, 2006."},{"key":"10.1016\/j.steroids.2020.108657_b0040","unstructured":"A. Steiner H. Waenerlund Poulsen E. Jolibois Preparation, Uses and Solid Forms of Obeticholic Acid PCT Int. Appl. WO2013\/192097, 2013."},{"issue":"13","key":"10.1016\/j.steroids.2020.108657_b0045","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.steroids.2012.09.002","article-title":"An improved synthesis of 6\u03b1-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR)","volume":"77","author":"Yu","year":"2012","journal-title":"Steroids"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X20300829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X20300829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:06:36Z","timestamp":1758535596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X20300829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":9,"alternative-id":["S0039128X20300829"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2020.108657","relation":{},"ISSN":["0039-128X"],"issn-type":[{"type":"print","value":"0039-128X"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Facial synthesis of key intermediate of obeticholic acid via Pd-catalyzed Kumada-Tamao-Corriu cross-coupling reaction","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2020.108657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108657"}}